I’ve always been interested in cancer and immunity. My research interests include hematologic malignancies, animal models and the pathophysiology of leukemia.
My work aims to understand leukemia biology and to identify effective treatments for this disease. I have developed numerous mouse models of human leukemia and identified various signaling pathways that can be targeted for additional research. I’m also an environmental activist working to address climate change.
I have more than 28 years’ experience and began working at Cincinnati Children’s in 2003. My research has been published in various respected journals, including Cancer Cell, Stem Cells, Blood, Leukemia, Science Translational Medicine and Experimental Hematology.
BA: St. Anselm College, Manchester, NH, 1986.
MS: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1989.
PhD: Rutgers University-University of Medicine and Dentistry, New Brunswick, NJ, 1992.
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Frontiers in Oncology. 2021; 11:642466.
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion. Cancer Cell. 2020; 38:79-96.e11.
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALL. Leukemia. 2020; 34:1241-1252.
Asymmetrically Segregated Mitochondria Provide Cellular Memory of Hematopoietic Stem Cell Replicative History and Drive HSC Attrition. Cell Stem Cell. 2020; 26:420-430.e6.
Rapid desensitization of humanized mice with anti-human FcεRIα monoclonal antibodies. Journal of Allergy and Clinical Immunology. 2020; 145:907-921.e3.
Improved chemotherapy modeling with RAG-based immune deficient mice. PloS one. 2019; 14:e0225532.
Global Gene Expression and Mutation Signatures Are Preserved in PDX Models of Pediatric AML and Aid Discovery of Targeted Therapy for Cases with CBFA2T3/GLIS2 Rearrangement. Blood. 2019; 134:3766.
Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood. 2019; 134:3934.
Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 2019; 11:eaaw8828.
Epigenetic Regulator Genes Direct the Fate of Multipotent Progenitor Cell of Origin in Lineage Switched MLL-AF4 Leukaemia. 2019.